Andrew Clausen

Andrew Clausen has extensive work experience in the pharmaceutical industry. Andrew is currently the Senior Vice President of Technical Operations CMC at Cerevel Therapeutics, where they previously served as the Vice President of Technical Operations. Prior to that, they were the Senior Director of Analytical Development at Cyclerion and the Senior Director at Ironwood Pharmaceuticals. From 2016 to 2018, they were the Vice President of Chemistry, Manufacturing and Control at Snapdragon Chemistry, Inc. Before that, they held various roles at Amgen, including Director of Commercial Biologic and Small Molecule Analytical Sciences and Director of Small Molecule Analytical Development. Earlier in their career, they worked at Merck & Co., Inc., where they held positions such as Associate Director and Research Fellow. Overall, Andrew has demonstrated expertise in technical operations, analytical development, and chemical process definition.

Andrew Clausen completed their education with a Bachelor of Science degree in Chemistry from Iowa State University in 1993. Andrew then pursued further studies and obtained a Ph.D. in Chemistry from the University of Minnesota between 1993 and 1998. Following this, from 2002 to 2010, Clausen pursued a Master of Engineering degree in Chemical Engineering from Lehigh University.